Skip Navigation


Brain Advance Access originally published online on June 23, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
127/8/1693    most recent
awh198v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (37)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Michell, A. W.
Right arrow Articles by Barker, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michell, A. W.
Right arrow Articles by Barker, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 127, No. 8, 1693-1705, August 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh198

Review article

Biomarkers and Parkinson's disease

A. W. Michell, S. J. G. Lewis, T. Foltynie and R. A. Barker

Cambridge Centre for Brain Repair, Cambridge, UK

Correspondence to: Dr A. W. Michell, Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, CB2 2PY, UK E-mail: awm13{at}cam.ac.uk

Biomarkers are characteristics that can be measured as an indicator of a normal biological process, and they have special relevance in Parkinson's disease. Parkinson's disease is a chronic neurodegenerative disorder that is difficult to study, given the site of pathology and because the resultant clinical phenotype fluctuates over time. We currently have no definitive diagnostic test, and thus for the clinician there is hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this heterogeneous disease. No biomarker is likely to fulfil all these functions, so we need to know how each has been validated in order to understand their uses and limitations, and be aware of potential pitfalls. In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
O. Rascol
"Disease-modification" trials in Parkinson disease: Target populations, endpoints and study design
Neurology, February 17, 2009; 72(7_Supplement_2): S51 - S58.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
C. H Hawkes and J. Deeb
Predicting Parkinson's disease: worthwhile but are we there yet?
Practical Neurology, October 1, 2006; 6(5): 272 - 277.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
L. M. L. de Lau, P. J. Koudstaal, A. Hofman, and M. M. B. Breteler
Subjective Complaints Precede Parkinson Disease: The Rotterdam Study
Arch Neurol, March 1, 2006; 63(3): 362 - 365.
[Abstract] [Full Text] [PDF]

Home page
 JWatch NeurologyHome page
Potential Biomarkers for Parkinson Disease
Journal Watch Neurology, November 5, 2004; 2004(1105): 7 - 7.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.